Business Context and Reporting Period
Company: ProMIS Neurosciences Inc. (PMN)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: ProMIS is a clinical-stage biopharmaceutical company developing antibody therapies and vaccines for neurodegenerative diseases, specifically Alzheimer's disease (AD), multiple system atrophy (MSA), and amyotrophic lateral sclerosis (ALS). The company utilizes a proprietary technology platform to target toxic, misfolded proteins. Key product candidates include PMN310 (AD), PMN267 (ALS), and PMN442 (MSA). The company has not generated any revenue to date.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 | Balance Sheet (Sept 30, 2025) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(11.58) million | $(29.05) million | N/A |
| Operating Expenses | $11.75 million | $29.40 million | N/A |
| Cash and Short-Term Investments | N/A | N/A | $15.43 million |
| Total Current Liabilities | N/A | N/A | $12.21 million |
| Accumulated Deficit | N/A | N/A | $(119.73) million |
| Net Cash Used in Operating Activities | N/A | $(18.84) million | N/A |
| Net Cash Provided by Financing Activities | N/A | $20.94 million | N/A |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased significantly to $29.40 million for the nine months ended September 30, 2025, compared to $10.83 million in the same period in 2024. This 172% increase was primarily driven by Research and Development (R&D) expenses, which rose to $24.01 million from $6.31 million.
- R&D Drivers: The surge in R&D costs is attributed to the commencement and ongoing execution of the Phase 1b clinical trial (PRECISE-AD) for the lead candidate PMN310, which began in late 2024. Direct costs for PMN310 increased by approximately $17.0 million year-over-year.
- Net Income/Loss: The company reported a net loss of $29.05 million for the nine months ended September 30, 2025, contrasting with a net income of $3.02 million in the prior year period. The prior year income was largely due to a non-cash gain of $17.0 million from the change in fair value of financial instruments (warrant liability), which did not recur in 2025.
- Share Count: Outstanding common shares increased from 32.69 million (Dec 31, 2024) to 53.81 million (Sept 30, 2025) due to equity financings and warrant exercises.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months. With cash of $15.4 million and negative operating cash flows, the company requires additional funding to sustain operations and clinical trials.
- Recent Financing: In July 2025, the company raised approximately $21.6 million in gross proceeds through a combination of discounted warrant exercises, private placements (PIPE), and a registered direct offering. This capital was critical to extending the runway.
- Clinical Progress: The Phase 1b trial for PMN310 is ongoing. As of November 12, 2025, Cohorts 1 and 2 are fully enrolled, and Cohort 3 is well underway. The FDA granted Fast Track Designation to PMN310 in July 2025. Topline results are expected in Q4 2026.
- Internal Control Material Weakness: The company identified a material weakness in internal controls over financial reporting related to insufficient review controls over fair value calculations of financial instruments (specifically the July 2024 PIPE warrant liability). Management is implementing remediation measures, but the weakness remains unremediated as of the filing date.
- Outlook: The company expects to continue incurring net losses for the foreseeable future as it advances clinical programs. Future funding will be sought through public/private equity, debt, or strategic collaborations.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $15.4 million cash balance against the burn rate of ~$18.8 million per nine months to assess the immediate need for further capital raises.
- Material Weakness Remediation: Monitor the progress of remediation efforts regarding the internal control weakness over fair value calculations to ensure future financial reporting reliability.
- PMN310 Clinical Data: Track the enrollment completion of Cohort 3 and the anticipated release of 6-month interim data in Q2 2026 and topline results in Q4 2026.
- Dilution Risk: Review the impact of the significant increase in share count (from ~32.7M to ~53.8M) and the large number of outstanding warrants (~66.3M) on future dilution.
- Accrued Liabilities: Investigate the sharp increase in accrued liabilities from $0.48 million (Dec 2024) to $8.0 million (Sept 2025), primarily driven by R&D accruals, to understand payment obligations.